A phase III, multicentre, randomised, investigator-masked, cross-over, comparative, non-inferiority trial evaluating the efficacy and tolerability of generic preservative-free Latanoprost (Polpharma S.A.) compared to Xalatan® (Pfizer) in patients with ocular hypertension or primary open-angle glaucoma

Peer Review reports

Original Submission
19 Dec 2023	Submitted	Original manuscript
24 Jan 2024	Author responded	Author comments - Norbert Czumbel
Resubmission - Version 2
24 Jan 2024	Submitted	Manuscript version 2
14 Jun 2024	Reviewed	Reviewer Report - Péter Kóthy
26 Jun 2024	Reviewed	Reviewer Report
16 Jul 2024	Author responded	Author comments - Norbert Czumbel
Resubmission - Version 3
16 Jul 2024	Submitted	Manuscript version 3
Publishing
17 Jul 2024	Editorially accepted
29 Jul 2024	Article published	10.1186/s12886-024-03579-3

Back to article page